Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution

Clinical Investigation to Evaluate the Haemonetics LeukoSep Leukocyte Reduction Filtration System for Whole Blood With CPD Anticoagulant and SOLX Additive - Pivotal Trial

This study will evaluate a new blood collection and filtration system that is intended to be used to collect, filter, separate and store red blood cells and, separately, plasma. The new blood collection and filtration system will be compared to an already-approved and currently used system. Further, this study will evaluate new processing conditions relative to the individual components of the collection and filtration system. All study participants will donate two units of whole blood with individual units being donated at least 56 days apart. One unit of whole blood will be donated with the new system, and the other unit will be collected with the already-approved system. A subset of the donors (approximately 24 of the 120 participants) will have a small quantity of their red blood cells injected back into their body 42-days after they were donated in order to evaluate how well the red blood cells survive. Blood and blood products from all donors will be analyzed the day of collection and after storage (plasma after at least 30 days of storage and red blood cells after exactly 42 days of storage).

Study Overview

• Status: Completed
• Conditions: Blood Donors
• Intervention / Treatment: Drug: SOLX (Investigational); Drug: AS-3 (Control)

Detailed Description

In vitro and in vivo performance of SOLX® RBCs produced with the modified SOLX® System will be used to demonstrate the acceptability of both the proposed product modification and expanded indications. To accomplish this, the study will require a total of 120 evaluable donors completing the study. Enrolled donors will be assigned to either of two study arms. Each study arm will entail a randomized, paired, 2-x-2 crossover design where every study donor (n = 60 evaluable study donors who complete the study per arm) will donate a total of two whole blood units with individual units being donated at least 56 days (8 weeks) apart. One unit will be collected with the investigational product (IP) and the other unit will be collected with the control product (CP). The order in which the IP and the CP will be used to collect, filter and store the whole blood and appropriate blood products (within the context of the crossover design) will be randomized.

Each of the two study arms will evaluate outcomes resulting from different storage, filtration and processing conditions:

• Arm 1 will entail holding whole blood units at 20-24°C after collection for ≥ 20 hours (IP) or ≥ 6 hours (CP) prior to initiating room temperature filtration. Following room temperature centrifugation and subsequent separation, SOLX® PRBC will be placed at 1-6°C and plasma placed at ≤ -18°C within 24 hours (IP) or within 8 hour (CP) of collection. The first donation will occur with product indicated per randomization and the second donation will occur with product alternate to the randomization. Arm 1 will further entail an in vivo double-radiolabelled autologous RBC recovery substudy (n = 20-24, paired IP and CP data will be collected) and an evaluation of pre- and post-rejuvenation PRBC 2,3-DPG levels (all IP and CP units). The in vivo substudy and rejuvenation evaluation is limited to only Arm 1 and is not included in Arm 2.
• Arm 2 will entail holding whole blood units at 1-6°C after collection for ≥ 66 hours (both IP and CP) prior to initiating cold filtration. Following refrigerated centrifugation and subsequent separation, SOLX® PRBCs will be placed at 1-6°C within 72 hours of collection (both IP and CP). Plasma will not be evaluated for this arm and will be discarded. The first donation will occur with product indicated per randomization and the second donation will occur with product alternate to the randomization.

For each study arm that does not meet the protocol-defined in vitro acceptance criteria for exactly 1 unit, an additional 71 evaluable donors will be enrolled, thus increasing the number of evaluable enrolled donors completing the respective study arm to 131 donors. Only those acceptance criteria endpoints that were not met within their respective study arm will be evaluated and neither matched/paired crossover controls nor in vivo RBC recovery (Arm 1 In vivo substudy) will be evaluated. If all protocol defined in vitro acceptance criteria are met or > 1 subject does not meet the protocol defined in vitro acceptance criteria relative to a specific study arm, then no enrollment will occur relative to the same study arm.

• Study Type: Interventional
• Enrollment (Actual): 170
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Ohio
    • Cincinnati, Ohio, United States, 45267
      • Hoxworth Blood Center
  • Virginia
    • Norfolk, Virginia, United States, 23507
      • American Red Cross Mid-Atlantic Region Blood Services

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age - Study donor must be ≥ 18 years of age
• Weight - Study donor must be ≥ 110 pounds
• Temperature - Study donor's body temperature must be ≤ 37.5°C / 99.5°F (oral)
• Hemoglobin - Study donor's hemoglobin must be ≥12.5 g/dL
• Hematocrit - Study donor's hematocrit must be ≥ 38%. Donor Eligibility - Study donor must meet all criteria per respective site's Research Blood Donation Record (BDR)
• Prior Donation - Study donor's most recent single RBC unit donation must have been ≥56 days prior to study donation. Study donor's most recent double RBC unit donation must have been ≥ 112 days prior to study donation
• Informed Consent - Study donor must have consented to study participation by reviewing and having expressed understanding the site-respective IRB-approved informed consent form prior to undergoing any study related procedures
• Blood-borne Pathogens - Study donor's testing results from collected blood does not indicate a risk of transfusion-transmitted disease (TTD)
• Adverse Events - Study donors must agree to report adverse events from the time of signing the informed consent to twenty-four hours following the end of their active study involvement
• Pregnancy - Female study donors must not be pregnant, expected to be pregnant or breastfeeding. Only female donors who participate in the in vivo portion of the study: Women of child-bearing age must not be pregnant as determined by a negative pregnancy test prior to each re-infusion. If acceptable by local procedures, post-menopausal or surgically sterile women may be exempt from the pregnancy testing requirement

Exclusion criteria:

-Failure to meet one or more of the above criteria

Study Plan

How is the study designed?

Design Details

• Primary Purpose: SUPPORTIVE_CARE
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Arm 1: Room Temperature Storage/Filtration; SOLX (Investigational Product) and AS-3 (Control)	Drug: SOLX (Investigational); SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.; Other Names: AS-7; Additive solution 7; Drug: AS-3 (Control); AS-3 solution is regulated as a drug but is not intended to provide a direct therapeutic benefit; Other Names: Additive solution formula 3
Other: Arm 2 : Cold storage; SOLX (Investigational Product) and AS-3 (Control)	Drug: SOLX (Investigational); SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.; Other Names: AS-7; Additive solution 7; Drug: AS-3 (Control); AS-3 solution is regulated as a drug but is not intended to provide a direct therapeutic benefit; Other Names: Additive solution formula 3

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Red Blood Cell Post-filtration Recovery	The percent of recovered red blood cells when the content of pre-filtration whole blood is compared to the post-filtration leukoreduced whole blood content.	Arm and product dependent (< 8 hours, 20-24 hours, 66-72 hours post collection)
Residual Leukocyte Count	The level of residual white blood cells in whole blood filtered after either <8 hours (AS-3) or 20-24hours (SOLX) of room temperature storage or cold storage for 72 hours.	<8 hours and 20-24 hours

Collaborators and Investigators

• Sponsor: Haemonetics Corporation
• Investigators: Principal Investigator: Lou A Maes, MD, ARC Mid-Atlantic Region Blood Services

Study record dates

Study Major Dates

• Study Start: April 1, 2014
• Primary Completion (Actual): December 1, 2014
• Study Completion (Actual): January 1, 2015

Study Registration Dates

• First Submitted: May 19, 2014
• First Submitted That Met QC Criteria: May 20, 2014
• First Posted (Estimate): May 23, 2014

Study Record Updates

• Last Update Posted (Actual): April 25, 2022
• Last Update Submitted That Met QC Criteria: March 25, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Keywords: Leukoreduction; Red Blood Cell post-leukoreduction recovery; Packed red blood cell post storage hemolysis; Red blood cell recovery; Plasma clotting factors; 2,3-DPG rejuvenation
• Additional Relevant MeSH Terms: Pharmaceutical Solutions
• Other Study ID Numbers: TP-CLN-100331